GSK, which also has phase 3 programmes running for depemokimab in EGPA and HES, has previously put a target peak sales figure of £3 billion ($3.9 billion) a year on the drug.

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD).

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio ...

Mike Bowman is a 30-year veteran of the hospitality and gaming industries, having worked in several senior level positions for Hilton Hotels, Wyndham Worldwide, Rush Gaming and Caesars Entertainment.

In addition to the Whitehall and forthcoming Lower Nazareth and Montgomeryville stores, other regional Bob’s locations operate in Spring Township, Berks County; and Upper Merion and Upper ...